Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY
In this analysis of CONFIDENCE and FIDELITY:
- Simultaneous finerenone + SGLT2i initiation achieved a comparable level of UACR reduction at least 3.5 months earlier than a sequential strategy.
- Serious adverse events were comparable between the strategies, although hyperkalemia events appeared more common with simultaneous initiation.
- Key limitation: indirect trial comparison - these findings should be interpreted as exploratory and in the context of differences in trial design and population.
This cross-trial analysis suggests that, with appropriate monitoring, simultaneous initiation of finerenone and a SGLT2i may be preferred to expedite cardiorenal risk reduction in CKD and T2D.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
